Tumour tissue collection

PROCEDURE3 trials

Sponsors

University Health Network, Toronto, AstraZeneca

Conditions

Gynecologic CancerSolid Tumor

Unknown Phase

Study of Biomarkers in Gynecological Cancers

RecruitingNCT03420118

University Health Network, TorontoGynecologic Cancer

Start: 2017-12-21End: 2027-12-21Target: 1000Updated: 2025-12-05

Study Looking at Biomarkers in Ovarian Cancer

RecruitingNCT03419689

University Health Network, TorontoGynecologic Cancer

Start: 2018-01-08End: 2028-06-08Target: 510Updated: 2025-12-04

Prospective Tissue Collection Research Protocol

CompletedNCT03517917

AstraZenecaSolid Tumor

Start: 2018-02-08End: 2024-10-08Updated: 2025-05-23

Related Papers

Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching.

Journal of Clinical Oncology2024-06-01

Molecular characterization of cervical cancer histological subtypes: The VENUS study.

Journal of Clinical Oncology2024-06-01

1312 Identification and validation of immunogenic clonal neoantigens for personalized therapies

Regular and Young Investigator Award Abstracts2023-10-31

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

2023-03-1518 citations

193 The Achilles VELOS<sup>TM</sup> Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies

Regular and Young Investigator Award Abstracts2021-11-01

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).

Journal of Clinical Oncology2021-05-205 citations

Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products

Cancer Research2020-08-153 citations

Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use

Cancer Research2020-08-15